36. Epidermolysis bullosa Clinical trials / Disease details


Clinical trials : 160 Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04613102
(ClinicalTrials.gov)
August 1, 202027/10/2020The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III TrialThe Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III TrialEpidermolysis Bullosa;Pain;ItchDrug: AVCN583601 (3% Cannabidiol cream)Elena PopeAvicanna IncWithdrawn4 Years50 YearsAll0Phase 2/Phase 3Canada
2EUCTR2021-000103-20-NL
(EUCTR)
15/07/2021A study on the effect of Transvamix on pain in adults with epidermolysis bullosa.An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa Genetic Epidermolysis Bullosa;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]Product Name: Transvamix (100mg/mL THC, 50mg/mL CBD)
INN or Proposed INN: THC
Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL
INN or Proposed INN: CBD
Other descriptive name: CANNABIDIOL
University Medical Center GroningenNULLNAFemale: yes
Male: yes
16Phase 2Netherlands